Abstract:Abstract Objective Stage I‐II uterine papillary serous carcinoma (UPSC) has aggressive biological behavior and leads to poor prognosis. However, clinicopathologic risk factors to predict cancer‐specific survival of patients with stage I‐II UPSC were still unclear. This study was undertaken to develop a prediction model of survival in patients with early‐stage UPSC. Methods Using Surveillance, Epidemiology, and End Results (SEER) database, 964 patients were identified with International Federation of Gynecology and Obstetrics (FIGO) stage I‐II UPSC who underwent at least hysterectomy between 2004 and 2015. By considering competing risk events for survival outcomes, we used proportional subdistribution hazards regression to compare cancer‐specific death (CSD) for all patients. Based on the results of univariate and multivariate analysis, the variables were selected to construct a predictive model; and the prediction results of the model were visualized using a nomogram to predict the cancer‐specific survival and the response to adjuvant chemotherapy and radiotherapy of stage I‐II UPSC patients. Results The median age of the cohort was 67 years. One hundred and sixty five patients (17.1%) died of UPSC (CSD), while 8.6% of the patients died from other causes (non‐CSD). On multivariate analysis, age ≥ 67 (HR = 1.45, P = .021), tumor size ≥ 2 cm (HR = 1.81, P = .014) and >10 regional nodes removed (HR = 0.52, P = .002) were significantly associated with cumulative incidence of CSD. In the age ≥67 cohort, FIGO stage IB‐II was a risk factor for CSD (HR = 1.83, P = .036), and >10 lymph nodes removed was a protective factor (HR = 0.50, P = .01). Both adjuvant chemotherapy combined with radiotherapy and adjuvant chemotherapy alone decreased CSD of patients with stage I‐II UPSC older than 67 years (HR = 0.47, P = .022; HR = 0.52, P = .024, respectively). The prediction model had great risk stratification ability as the high‐risk group had higher cumulative incidence of CSD than the low‐risk group (P < .001). In the high‐risk group, patients with post‐operative adjuvant chemoradiotherapy had improved CSD compared with patients who did not receive radiotherapy nor chemotherapy (P = .037). However, there was no such benefit in the low‐risk group. Conclusion Our prediction model of CSD based on proportional subdistribution hazards regression showed a good performance in predicting the cancer‐specific survival of early‐stage UPSC patients and contributed to guide clinical treatment decision, helping oncologists and patients with early‐stage UPSC to decide whether to choose adjuvant therapy or not.

Lower Uterine Segment Involvement as a Predictor for Poor Prognosis in Patients Receiving Adjuvant Radiotherapy for Stage I Endometrial Carcinoma

Lower Uterine Segment Involvement is Associated with Poor Outcomes in Early-Stage Endometrioid Endometrial Carcinoma

The Clinicopathological Features and Prognoses of Lower Uterine Segment Cancer: A Retrospective, Single-Center Cohort Study

Lymphovascular Space Invasion (LVSI)-Based Prognostic Clusters in Endometrial Cancer Patients Treated with Primary Surgery and Adjuvant Radiotherapy

The Value of Lymph Node Ratio in the Prediction of Rectal Cancer Patient Survival after Preoperative Chemoradiotherapy.

Prognostic Significance of Lymphovascular Space Invasion in the Absence of Lymph Node Metastases in Early-Stage Endometrial Cancer

Postoperative Adjuvant Treatment in Women with Stage I Endometrial Cancer: A Retrospective Study

Ten-Year Results of Postoperative Adjuvant Treatment In Women With Stage I Endometrial Cancer

Guiding adjuvant radiotherapy in stage III endometrial cancer: a prognostic model based on SEER

[Combined Treatment and Prognostic Factors for Stage III and IV Endometrial Carcinoma].

Combined treatment and prognostic factors for stage Ⅲ and Ⅳ endometrial carcinoma

Prognostic significance of lymphovascular space invasion in early-stage low-grade endometrioid endometrial cancer: a fifteen-year retrospective Chinese cohort study

ER predicts poor prognosis in male lung squamous cell cancer of stage IIIA-N2 disease after sequential adjuvant chemoradiotherapy

[Predictors of Recurrence and Prognosis in Patients with Stage I and II Endometrial Carcinoma].

Prognostic evaluation of lymph-vascular space invasion in patients with endometrioid and non-endometrioid endometrial cancer: A multicenter study

Impact of adjuvant treatment on survival in patients with 2023 FIGO stage IIC endometrial cancer: a retrospective analysis from two tertiary centers in Korea and Taiwan

Article Evaluation of treatment strategies and prognostic factors of 135 patients with low-grade endometrial stromal sarcoma

Who benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-dimensional model for candidate selection

A Novel Model to Predict Cancer-Specific Survival in Patients with Early-Stage Uterine Papillary Serous Carcinoma (UPSC).

Quantification of recurrence risk based on number of adverse prognostic factors in women with stage I uterine endometrioid carcinoma

Low-Grade Endometrial Stromal Sarcoma and Uterine Adenosarcoma: A Comparison of Clinical Manifestations and Outcomes.